Whereas silencing PNPLA3 does not lead to a disease phenotype (127), overexpression of the mutant PNPLA3‐148M variant generally has accelerated steatosis and some inflammation but not steatohepatitis with fibrosis. This evidence concerns the gene PNPLA3 and steatosis.